Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2026 09:00 ET | Source: Navigator Medicines INC

Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026

First Patient Dosed (FPD) in Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS)Phase 1b Multiple Ascending Dose Study Demonstrates Favorable Profile for NAV-240 First Participant...
March 27, 2026 08:00 ET | Source: OnKure Therapeutics, Inc.

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer...
March 27, 2026 08:00 ET | Source: OXB

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene...
March 27, 2026 08:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple

La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple ...
March 27, 2026 08:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating...
March 27, 2026 07:56 ET | Source: Arletta Pharma Solutions

Arletta Pharma Solutions Announces Positive Results from Phase II Clitoral Doppler Duplex Ultrasound Study of Lybrido™ Combination Targeting Female Sexual Dysfunction

Arletta Pharma reports >60% clitoral blood flow improvement with Lybrido™ in Phase II study, achieving statistical significance in women with FSIAD.
March 27, 2026 04:00 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Solicita Autorização de Comercialização de Palsonify™ (Paltusotina) no Brasil para Tratamento de Acromegalia

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- A Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) anunciou hoje que deu entrada em um Pedido de Autorização de Comercialização (MAA) à Agência Nacional...
March 26, 2026 20:02 ET | Source: Radiant Health Centers

Radiant Health Centers Names Mark Gonzales Interim CEO Amid Period of Expansion

Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers today announced the appointment of Mark Gonzales as Interim Chief Executive Officer, ushering in a new chapter of leadership...
March 26, 2026 16:32 ET | Source: Open Space Institute

Governor Henry McMaster, Open Space Institute, South Carolina State Parks Celebrate the Opening of State’s First-Ever Riverine Park Network

WILLIAMSBURG COUNTY, S.C., March 26, 2026 (GLOBE NEWSWIRE) -- Gov. Henry McMaster, the Open Space Institute (OSI), South Carolina Department of Parks, Recreation & Tourism (SCPRT), and...
March 26, 2026 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health...